MedTrace Logo

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 512

Last updated 2017-09-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).

Conditions

  • Atopic Disease (Including Allergic Conjunctivitis)

Interventions

DRUG

Drug: AC-170 0.24%

DRUG

AC-170 0%

Sponsors & Collaborators

  • Aciex Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Stacey L Ackerman, MD · Philadelphia Eye Associates

  • Dawn K De Castro, MD · Andover Eye Associates

  • Edward J Meier, MD · Apex Eye

  • Eugene E Protzko, MD · Seidenberg Protzko Eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02132169 on ClinicalTrials.gov